Binds A Lymphokine, Cytokine, Or Other Secreted Growth Regulatory Factor, Differentiation Factor, Intercellular Mediator Specific For A Hematopoietic Cell (e.g., Interleukin, Interferon, Erythropoietin, Etc.) Patents (Class 435/335)
-
Patent number: 8753632Abstract: High-specificity antibodies can distinguish between modified (e.g, hIGF-1/Ea 3mut) and endogenous wild-type human IGF-1 proteins. These antibodies have little or no cross-reactivity with hIGF-1 or hIGF-2. They also have little or no cross-reactivity with rodent IGF-1 or IGF-2. The antibodies can be used in pharmacokinetic (PK)/pharamcodynamic (PD) assessments of IGF-1/E peptides that have been administered to humans or animals. A sandwich ELISA assay, using the antibody of the invention as a capture antibody, can quantify the mutant IGF-1/E proteins in samples.Type: GrantFiled: November 10, 2009Date of Patent: June 17, 2014Assignee: Novartis AGInventors: Mara Fornaro, John Xu, Yuan Gao, Rainer Hillenbrand, Francois Legay, Daniela Stoellner
-
Publication number: 20140154255Abstract: The present disclosure relates to antibodies directed to vascular endothelial growth factor (“VEGF”) and uses of such antibodies, for example to treat diseases associated with the activity and/or overproduction of VEGF.Type: ApplicationFiled: November 26, 2013Publication date: June 5, 2014Applicant: AbbVie Biotherapeutics Inc.Inventor: Yoshiko AKAMATSU
-
Patent number: 8741295Abstract: The invention relates to PD-1 antibodies and PD-L1 antibodies and uses thereof.Type: GrantFiled: February 9, 2010Date of Patent: June 3, 2014Assignees: Universite de la Mediterranee, Inserm (Institut National de la Sante et de la Recherche Medicale)Inventor: Daniel Olive
-
Publication number: 20140141012Abstract: The invention relates to binding compounds that specifically bind to human TSLP, as well as uses thereof, e.g., in the treatment of inflammatory disorders and allergic inflammatory response.Type: ApplicationFiled: January 28, 2014Publication date: May 22, 2014Applicant: MERCK SHARP & DOHME CORP.Inventor: Leonard G. Presta
-
Publication number: 20140141011Abstract: The invention relates to binding compounds that specifically bind to human TSLP, as well as uses thereof, e.g., in the treatment of inflammatory disorders.Type: ApplicationFiled: October 8, 2013Publication date: May 22, 2014Applicant: SCHERING CORPORATIONInventors: LEONARD G. PRESTA, RENE DE WAAL MALEFYT
-
Publication number: 20140134176Abstract: The present invention provides antibodies, or antigen-binding fragment thereof, which specifically bind to PDGF-B. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of PDGF-B mediated diseases, disorders or conditions.Type: ApplicationFiled: November 8, 2013Publication date: May 15, 2014Applicant: Pfizer Inc.Inventors: Robert ARCH, Gregory CARVEN, Jun KUAI, Lydia MOSYAK, Shinji OGAWA, Dirk PONSEL, Robert RAUCHENBERGER
-
Publication number: 20140134674Abstract: The invention describes improved methods and compositions for producing a recombinant protein, e.g., an antibody, in mammalian cell culture. In addition, the invention provides improved cell culture media, including improved production media, feed solutions, and combination feeds, which may be used to improve protein productivity in mammalian cell culture.Type: ApplicationFiled: January 16, 2014Publication date: May 15, 2014Applicant: ABBVIE INC.Inventors: Joseph C. Matuck, Thomas Seewoester, Yu-Hsiang David Chang, James McIntire, Nicole A. Roy, John C. Fann, Christof Schulz, David F. Bruton, Itzcoatl A. Pla
-
Publication number: 20140134183Abstract: The present invention relates to anti-IL-1 beta binding members and in particular to monovalent high potency IL-1 beta-binding antibody fragments being highly stable and soluble. Such binding members may be used in the treatment of inflammatory and other diseases as well as in diagnostics. Also provided are related nucleic acids, vectors, cells, and compositions.Type: ApplicationFiled: November 5, 2013Publication date: May 15, 2014Applicant: Delenex Therapeutics AGInventors: Stefanie Grabulovski, Titus Kretzschmar, Simone Schmitt, Abdijapar Shamshiev
-
Publication number: 20140127230Abstract: The present invention relates to antibody molecules, in particular antibody molecules that bind Transforming Growth Factor beta (TGF?), and uses thereof. More particularly, the invention relates to antibody molecules that bind and preferably neutralise TGF?1, TGF?2 and TGF?3, so-called “pan-specific” antibody molecules, and uses of such antibody molecules. Preferred embodiments within the present invention are antibody molecules, whether whole antibody (e.g. IgG, such as IgG1 or IgG4) or antibody fragments (e.g. scFv, Fab, dAb).Type: ApplicationFiled: October 21, 2013Publication date: May 8, 2014Inventors: Steven R. Ledbetter, Celia Patricia Hart, Robert G. Holgate, Lutz U. Jermutus, Catriona L. Buchanan, Alexander R. Duncan, Donna K. Finch
-
Patent number: 8715963Abstract: Described is a method for increasing the N-glycosylation site occupancy of a therapeutic glycoprotein produced in recombinant host cells modified as described herein and genetically engineered to express the glycoprotein compared to the N-glycosylation site occupancy of the therapeutic glycoprotein produced in a recombinant host cell not modified as described herein. In particular, the method provides recombinant host cells that overexpress a heterologous single-subunit oligosaccharyltransferase, which in particular embodiments is capable of functionally suppressing the lethal phenotype of a mutation of at least one essential protein of the yeast oligosaccharyltransferase (OTase) complex, for example, the Leishmania major STT3D protein, in the presence of expression of the host cell genes encoding the endogenous OTase complex.Type: GrantFiled: February 23, 2011Date of Patent: May 6, 2014Assignee: Merck Sharp & Dohme Corp.Inventors: Natarajan Sethuraman, Byung-Kwon Choi, Bianka Prinz, Michael Meehl, Terrance Stadheim
-
Patent number: 8715941Abstract: Anti-LRP6 antibodies and antigen-binding fragments thereof, as well as pharmaceutical compositions comprising such antibodies and antigen-binding fragments are described. These anti-LRP6 antibodies can be used to enhance Wnt activity and/or antagonize Dkk1 activity. Also described are methods of therapy using such antibodies and antigen-binding regions to bind modulate Wnt/LRP6 signaling to promote tissue homeostasis, regeneration and repair in diseases such as, but not limited to, bone disorders, such as osteoporosis, rheumatoid arthritis, and osteolytic lesions caused by osteoarthritis and multiple myeloma, gastrointestinal disease and wound healing.Type: GrantFiled: November 14, 2008Date of Patent: May 6, 2014Assignee: Arca Biopharma, Inc.Inventors: Arie Abo, Minke Binners
-
Publication number: 20140112935Abstract: The present disclosure provides antibodies that bind to human interleukin-6 (IL6). The antibodies can modulate IL6 signaling and thus used in treatment or prevention of IL6 associated diseases or disorders, particularly inflammatory disorder, rheumatoid arthritis (RA), angiogenesis, and cancer.Type: ApplicationFiled: October 18, 2013Publication date: April 24, 2014Applicant: Fountain Biopharma Inc.Inventors: Willie Lin, Tong-Young Lee, Han-Chung Wu, Tanny Chen Tsao
-
Publication number: 20140099671Abstract: Proteins that bind IL-1? and IL-1? are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1? and IL-1? in cells, tissues, samples, and compositions.Type: ApplicationFiled: December 12, 2013Publication date: April 10, 2014Applicant: ABBVIE, INC.Inventors: Chengbin WU, Dominic J. AMBROSI, Chung-ming HSIEH, Tariq GHAYUR
-
Patent number: 8685669Abstract: The invention provides humanized mouse anti-human IL-31 antibodies and antibody fragments that are capable of binding IL-31 and thereby neutralizing, inhibiting, limiting, or reducing the proinflammatory or pro-pruritic effects of IL-31.Type: GrantFiled: June 3, 2013Date of Patent: April 1, 2014Assignees: ZymoGenetics, Inc., Merck Serono S/AInventors: Kent Bondensgaard, Roland Beckmann
-
Patent number: 8679502Abstract: Disclosed herein are anti-hGM-CSF monoclonal antibodies and antigen-binding fragments of such antibodies, with improved neutralizing capacity to hGM-CSF activity. Pharmaceutical compositions comprising such an antibody or antigen-binding fragment are also provided. The present invention is useful for the treatment of various diseases that are associated with aberrant expression of hGM-CSF.Type: GrantFiled: November 12, 2008Date of Patent: March 25, 2014Assignees: Evec Inc., Boehringer Ingelheim International GmbHInventors: Kenzo Takada, Kantou Nakajima, Barbara Kistler, John Park
-
Publication number: 20140079716Abstract: The instant invention is based, at least in part on the identification of a new class of antibodies that result, e.g., in improved LT blocking capabilities. Methods of making the subject binding molecules and methods of using the binding molecules of the invention to antagonize LT?R signaling are also provided.Type: ApplicationFiled: March 14, 2013Publication date: March 20, 2014Applicant: BIOGEN IDEC MA INC.Inventor: BIOGEN IDEC MA INC.
-
Publication number: 20140079719Abstract: An IL-17 binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-17 mediated disease or disorder, e.g. rheumatoid arthritis.Type: ApplicationFiled: November 20, 2013Publication date: March 20, 2014Applicant: Novartis AGInventors: Franco E. Di Padova, Hermann Gram, Hans Hofstetter, Margit Jeschke, Jean-Michel Rondeau, Wim Van Den Berg
-
Patent number: 8668909Abstract: The present invention relates to monoclonal antibodies and antigen-binding portions thereof that specifically bind to the C-terminal or the center region of macrophage migration inhibitory factor (MIF). These anti-MIF antibodies and antigen-binding portions thereof further inhibit human MIF biological function. The invention also relates to isolated heavy and light chain immunoglobulins derived from anti-MIF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to a method of identifying anti-MIF antibodies, pharmaceutical compositions comprising these antibodies and a method of using these antibodies and compositions for the treatment of MIF-related conditions.Type: GrantFiled: April 26, 2010Date of Patent: March 11, 2014Assignees: Baxter International Inc., Baxter Healthcare S.A., Dyax Corp.Inventors: Randolf Kerschbaumer, Friedrich Scheiflinger, Manfred Rieger, Michael Thiele, Geert C. Mudde, Juergen Muellberg, Rene Hoet
-
Publication number: 20140065674Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.Type: ApplicationFiled: November 8, 2013Publication date: March 6, 2014Applicant: UCB PHARMA S.A.Inventors: RALPH ADAMS, TERENCE SEWARD BAKER, ALASTAIR DAVID GRIFFITHS LAWSON
-
Publication number: 20140045215Abstract: The present invention relates to novel humanized, chimeric and murine antibodies that have binding specificity for the human CC chemokine ligand 20 (CCL20). The present invention further relates to heavy chains and light chains of said antibodies. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a heavy chain and/or a light chain of said antibodies, and to a method of preparing said antibodies. The anti-CCL20 antibodies of the invention can be used in therapeutic applications to treat, for example, inflammatory and autoimmune disorders and cancer.Type: ApplicationFiled: June 21, 2013Publication date: February 13, 2014Inventors: Toshio Imai, Brad Kline, Tetsu Kawano, Luigi Grasso, Yoshimasa Sakamoto, Jared Spidel, Miyuki Nishimura, Kenzo Muramoto, Tatsuo Horizoe
-
Patent number: 8648175Abstract: The present invention provides a new stable pharmaceutical composition of erythropoietin (EPO) that is stabilized with PVP.Type: GrantFiled: November 8, 2002Date of Patent: February 11, 2014Assignee: Lek Pharmaceuticals d.d.Inventors: Andreja Vukmirovic, Tanja Rozman Peterka, Jelka Svetek, Alenka Paris
-
Patent number: 8642741Abstract: A fully human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human TNF-like ligand 1A (hTL1A) is provided. The human anti-hTL1A antibodies are useful in treating diseases or disorders associated with TL1A, such as inflammatory diseases or disorders, e.g., inflammatory bowel diseases, including ulcerative colitis and Crohn's disease, rheumatoid arthritis, and the like; autoimmune diseases or disorders, such as multiple sclerosis, diabetes, and the like; and allergic reactions, such as asthma and allergic lung inflammation.Type: GrantFiled: November 8, 2011Date of Patent: February 4, 2014Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Brendan J. Classon, Dimitris Skokos
-
Publication number: 20140024077Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of IL-6, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.Type: ApplicationFiled: June 27, 2013Publication date: January 23, 2014Applicant: UCB Pharma S.A.Inventors: Richard Evan Gelinas, Mitra Choudhury Singhal, Yi Zhang, Andrew George Popplewell, Ralph Adams
-
Publication number: 20140023644Abstract: The present disclosure relates, in general, to materials and methods for antibodies specific for transforming growth factor beta (TGF?), including TGF?1, TGF?2 and TGF?3, and uses of these antibodies in the treatment of subjects having cancer, an eye disease, condition or disorder, fibrosis, including ophthalmic fibrosis or fibrosis of the eye, and other conditions or disorders related to TGF? expression.Type: ApplicationFiled: September 26, 2013Publication date: January 23, 2014Applicant: XOMA Technology Ltd.Inventors: Daniel Bedinger, Shireen S. Khan, Amer Mirza, Ajay J. Narasimha, Toshihiko Takeuchi
-
Publication number: 20140023651Abstract: Provided herein are methods, compositions, and uses relating to inhibitors of stem cell factor. For example, provided herein are antibodies targeting stem cell factor and methods for treating fibrotic and tissue remodeling diseases.Type: ApplicationFiled: July 9, 2013Publication date: January 23, 2014Inventors: Nicholas W. Lukacs, Vladislav A. Dolgachev, Steven L. Kunkel, Cory M. Hogaboam, Sem H. Phan
-
Publication number: 20140004125Abstract: An IL-1? binding antibody or IL-1? binding fragment thereof comprising the amino acid sequence of SEQ ID NO: 2, and related nucleic acids, vectors, cells, and compositions, as well as method of using same to treat or prevent a disease, and a method of preparing an affinity matured IL-1? binding polypeptide. IL-1? binding antibodies or IL-1? binding fragments thereof are provided which have desirable affinity and potency.Type: ApplicationFiled: January 11, 2013Publication date: January 2, 2014Applicant: XOMA TECHNOLOGY LTD.Inventor: Xoma Technology Ltd.
-
Publication number: 20130344086Abstract: The invention provides antibodies that are modified to reduce aggregration propensity, and methods of producing such antibodies. The present invention also provides particularly stable and soluble scFv antibodies and Fab fragments specific for TNF, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNF, and low immunogenicity. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.Type: ApplicationFiled: August 28, 2013Publication date: December 26, 2013Applicant: ESBATech, An Alcon Biomedical Research Unit LLCInventors: Leonardo Jose Borras, David Urech
-
Publication number: 20130336975Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for NGF. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-NGF antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-NGF antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-NGF antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with NGF.Type: ApplicationFiled: March 15, 2013Publication date: December 19, 2013Inventors: Benjamin H. Dutzar, Brian R. Kovacevich, Patricia Dianne McNeill, Danielle M. Mitchell, Ethan W. Ojala, Pei Fan, Jens Billgren, Erica A. Stewart, Corinne C. Akatsuka, Betty Yu-Ching Chang, John A. Latham, Leon F. Garcia-Martinez
-
Patent number: 8603778Abstract: The present invention relates to anti-TNF antibodies comprising all of the heavy chain variable CDR regions of SEQ ID NOS:1, 2 and 3 and/or all of the light chain variable CDR regions of SEQ ID NOS:4, 5 and 6, specific for at least one human tumor necrosis factor alpha (TNF) protein or fragment thereof, as well as nucleic acids encoding such anti-TNF antibodies, complementary nucleic acids, vectors, host cells, production methods and therapeutic methods.Type: GrantFiled: July 12, 2012Date of Patent: December 10, 2013Assignee: Janssen Biotech, Inc.Inventors: George Heavner, David M. Knight, Jill Giles-Komar, Bernard Scallon, David Shealy
-
Publication number: 20130323237Abstract: The present invention relates to human thymic stromal lymphopoietin (hTSLP) antibodies and especially those which neutralize hTSLP activity. It further relates to methods for using anti-hTSLP antibody molecules in diagnosis or treatment of hTSLP related disorders, such as asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.Type: ApplicationFiled: March 15, 2013Publication date: December 5, 2013Inventors: Michael BARDROFF, Matthew EDWARDS, Mehmet TUR, Olaf RATSCH
-
Patent number: 8597648Abstract: The present invention provides a full human anti-TNF-? monoclonal antibody, the preparation method and use thereof. The antibody in the present invention has an amino acid sequence of heavy chain variable region as shown in SEQ ID NO: 6 and an amino acid sequence of light chain variable region as shown in SEQ ID NO: 8. The antibody in the present invention can be used to prepare medicines for the treatment of autoimmune disorders.Type: GrantFiled: April 16, 2010Date of Patent: December 3, 2013Assignee: Shanghai Biomabs Pharmaceuticals Co., Ltd.Inventors: Huaizu Guo, Chuan Li, Xin Tong
-
Patent number: 8586037Abstract: The invention provides the antibody D9.2 and antibody molecules based on D9.2 which bind interleukin-17 receptor B. These may be useful in therapy, e.g. the treatment of asthma, ulcerative colitis or Crohn's disease.Type: GrantFiled: March 31, 2010Date of Patent: November 19, 2013Assignee: Medical Research CouncilInventors: Andrew Neil James McKenzie, Daniel Neill
-
Publication number: 20130295113Abstract: The present disclosure provides compositions and methods relating to antibodies that specifically bind to human erythropoietin. The disclosure provides nucleic acids encoding such antibodies and methods of making and using such antibodies.Type: ApplicationFiled: May 7, 2013Publication date: November 7, 2013Inventors: Daniel T. Mytych, Narendra Chirmule, Dohan K. Weeraratne
-
Patent number: 8575316Abstract: Provided is a pharmaceutical composition for treating and/or preventing abnormal bone metabolism targeting a protein encoded by a gene strongly expressed in osteoclasts. Specifically provided is a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation, and the like.Type: GrantFiled: April 7, 2010Date of Patent: November 5, 2013Assignee: Daiichi Sankyo Company, LimitedInventors: Yoshiharu Hiruma, Eisuke Tsuda, Takeshi Takizawa, Makiko Nakayama
-
Publication number: 20130280266Abstract: Antibodies and antigen-binding portions thereof that bind to human IL-6 are provided. Also provided are nucleic acids encoding such antibodies and antigen binding portions, methods of making such antibodies and antigen binding portions, compositions comprising such antibodies or antigen binding portions, and uses of such antibodies or antigen binding portions.Type: ApplicationFiled: April 5, 2013Publication date: October 24, 2013Applicants: BRISTOL-MYERS SQUIBB COMPANY, PFIZER INC.Inventors: Arvind Rajpal, Madhav Narasimha Devalaraja, Kristopher Toy, Lan Yang, Haichun Huang, Jun Z. Zhang, Peter Brams, Brigitte Devaux, David B. Passmore
-
Patent number: 8563271Abstract: Compositions and methods relating to antibodies that specifically bind to TGF-beta binding proteins are provided. These methods and compositions relate to altering bone mineral density by interfering with the interaction between a TGF-beta binding protein sclerostin and a TGF-beta superfamily member, particularly a bone morphogenic protein. Increasing bone mineral density has uses in diseases and conditions in which low bone mineral density typifies the condition, such as osteopenia, osteoporosis, and bone fractures.Type: GrantFiled: August 22, 2012Date of Patent: October 22, 2013Assignee: UCB Manufacturing, Inc.Inventors: David G. Winkler, Jiye Shi, John Latham
-
Publication number: 20130273064Abstract: The present invention relates to a binding compound which binds to human APRIL. More specifically the invention provides, compositions of anti-APRIL specific antibodies and methods to use such antibodies in modulating the biological activity APRIL, particularly in inflammatory diseases, inhibition of cell proliferation and cancer.Type: ApplicationFiled: March 11, 2013Publication date: October 17, 2013Applicant: BIONOVION HOLDING B.V.Inventors: Jan Paul Medema, Hans Van Eenennaam, Marco Guadagnoli, Fiona Clare Kimberley, Uyen Truong Phan
-
Publication number: 20130266581Abstract: Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications.Type: ApplicationFiled: June 25, 2013Publication date: October 10, 2013Inventors: Germaine FUH, Hans-Peter Gerber, Wei-Ching Liang, Frederic Fellouse, Sachdev S. Sidhu, Christian Wiesmann
-
Publication number: 20130259868Abstract: Complexes containing one or more modular recognition domains (MRDs) and MRDs attached to scaffold's including antibodies are described. The manufacture of these complexes are the use of these complexes to treat and diagnose diseases and disorders are also described.Type: ApplicationFiled: March 15, 2013Publication date: October 3, 2013Inventors: Viktor ROSCHKE, David Lafleur, David M. Hilbert, Peter Kiener
-
Publication number: 20130259799Abstract: Antigen binding proteins that bind to human GM-CSF protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of GM-CSF to GM-CSFR, inhibit GM-CSF-induced proliferation and signaling of myeloid lineage cell lines and inhibit GM-CSF-induced activation of human monocytes.Type: ApplicationFiled: June 11, 2013Publication date: October 3, 2013Inventors: Jacqueline A. Kirchner, Kenneth A. Brasel, Kara Olson, Jose Carlos Escobar, Dauphine Barone
-
Patent number: 8545849Abstract: The invention provides antibodies that are modified to reduce aggregration propensity, and methods of producing such antibodies. The present invention also provides particularly stable and soluble scFv antibodies and Fab fragments specific for TNF, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNF, and low immunogenicity. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.Type: GrantFiled: October 21, 2011Date of Patent: October 1, 2013Assignee: ESBATech, an Aclon Biomedical Research Unit LLCInventors: Leonardo Jose Borras, David Urech
-
Publication number: 20130254912Abstract: The present invention provides isolated anti-interferon alpha monoclonal antibodies, particularly human monoclonal antibodies, that inhibit the biological activity of multiple interferon (IFN) alpha subtypes but do not substantially inhibit the biological activity of IFN alpha 21 or the biological activity of either IFN beta or IFN omega. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the biological activity of IFN alpha using the antibodies of the invention, as well as methods of treating disease or disorders mediated by IFN alpha, such as autoimmune diseases, transplant rejection and graft versus host disease, by administering the antibodies of the invention.Type: ApplicationFiled: June 4, 2013Publication date: September 26, 2013Applicant: Medarex, Inc.Inventors: Alison Witte, Denise Williams, Josephine M. Cardarelli, David King, David B. Passmore
-
Patent number: 8541203Abstract: Activatable binding polypeptides (ABPs), which contain a target binding moiety (TBM), a masking moiety (MM), and a cleavable moiety (CM) are provided. Activatable antibody compositions, which contain a TBM containing an antigen binding domain (ABD), a MM and a CM are provided. Furthermore, ABPs which contain a first TBM, a second TBM and a CM are provided. The ABPs exhibit an “activatable” conformation such that at least one of the TBMs is less accessible to target when uncleaved than after cleavage of the CM in the presence of a cleaving agent capable of cleaving the CM. Further provided are libraries of candidate ABPs, methods of screening to identify such ABPs, and methods of use. Further provided are ABPs having TBMs that bind VEGF, CTLA-4, or VCAM, ABPs having a first TBM that binds VEGF and a second TBM that binds FGF, as well as compositions and methods of use.Type: GrantFiled: March 2, 2012Date of Patent: September 24, 2013Assignees: The Regents of the University of California, CytomX Therapeutics, Inc.Inventors: Patrick Sean Daugherty, Nancy Stagliano, Jerry Thomas, James W. West, Jason Sagert
-
Publication number: 20130236471Abstract: The present invention relates to anti-IL-36R binding compounds, in particular new anti-IL-36R antibodies and therapeutic and diagnostic methods and compositions for using the same.Type: ApplicationFiled: November 14, 2012Publication date: September 12, 2013Applicant: Boehringer Ingelheim GmbHInventors: Su-Ellen BROWN, Keith Canada, Lukasz Chlewicki, Michael Howell, Detlev Mennerich, Joseph Robert Woska, JR.
-
Publication number: 20130230886Abstract: Provided herein are antibodies, antigen binding portions, and derivatives thereof that are capable of binding tumor necrosis factor alpha (TNF?); nucleic acids encoding the antibodies, antigen binding portions, and derivatives thereof, including complementary nucleic acids; vectors; and host cells containing the nucleic acids.Type: ApplicationFiled: March 13, 2013Publication date: September 5, 2013Inventors: Christian Votsmeier, Uwe Gritzan, Kornelia Kirchner, Michael Strerath, Kerstin Baral, Ulrich Haupts, Wayne M. Coco, Susanne Steinig, Andreas Scheidig, Klaus Pellengahr, Simone Brückner, Hanna Plittersdorf, Peter Scholz, Jan Tebbe
-
Publication number: 20130230541Abstract: Antibody molecules, in particular fully human antibodies that bind to human IGF-1 and cross-react with IGF-2 such that binding of IGF-1 and IGF-2 to the IGF-1 receptor is prevented and IGF-1 receptor-mediated signaling is inhibited. The antibodies do not bind to insulin and thus do not affect the mitogenic properties of insulin that are mediated by its binding to the insulin receptors. The antibodies are useful for the treatment of hyperproliferative diseases, in particular cancer.Type: ApplicationFiled: October 17, 2012Publication date: September 5, 2013Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Paul ADAM, Eric BORGES
-
Publication number: 20130209489Abstract: There are disclosed selective myostatin antagonists (including antibodies), nucleic acids encoding them, and methods of making and using them. Neutralizing antibodies recognizing the conformational epitope near position 21 to 31 and position 50 to 60.Type: ApplicationFiled: August 15, 2011Publication date: August 15, 2013Inventors: Huiquan Han, Taruna Arora, Qing Chen, Hsieng Sen Lu, Xiaolan Zhou
-
Publication number: 20130202615Abstract: Provided are monoclonal antibodies and antigen binding fragments thereof that specifically bind vascular endothelial growth factor (VEGF). The anti-VEGF monoclonal antibodies block VEGF binding to its receptors (e.g., VEGFR1 and/or VEGFR2) and prevent phosphorylation of VEGFR2 by VEGF. Also provided are methods of using the monoclonal anti-VEGF antibodies for treatment of disease, including cancer.Type: ApplicationFiled: June 14, 2011Publication date: August 8, 2013Applicant: VACCINEX, INC.Inventors: Leslie A. Croy, Mark J. Paris, Ernest S. Smith
-
Publication number: 20130171143Abstract: The present invention relates to particularly stable and soluble scFv antibodies and Fab fragments specific for TNF?, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNF?, and low immunogenicity. Said antibodies are designed for the diagnosis and/or treatment of TNF?-related disorders. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.Type: ApplicationFiled: December 7, 2012Publication date: July 4, 2013Applicant: ESBATECH, AN ALCON BIOMEDICAL RESEARCH UNIT LLC.Inventor: ESBATECH, AN ALCON BIOMEDICAL RESEAR
-
Publication number: 20130171096Abstract: Proteins that bind sclerostin or sclerostin and TNF are described along with there use in composition and methods for treating, preventing, and diagnosing sclerostin related diseases and for detecting sclerostin or sclerostin and TNF in cells, tissues, samples, and compositions.Type: ApplicationFiled: October 24, 2012Publication date: July 4, 2013Applicant: AbbVie Inc.Inventors: Chung-Ming Hsieh, Alexander Ivanov, Wendy Waegell